Collegium Pharmaceutical to Post FY2021 Earnings of $2.06 Per Share, Piper Jaffray Forecasts (NASDAQ:COLL)

Collegium Pharmaceutical (NASDAQ:COLL) – Investment analysts at Piper Jaffray dropped their FY2021 earnings estimates for shares of Collegium Pharmaceutical in a report released on Wednesday, May 9th, according to Zacks Investment Research. Piper Jaffray analyst D. Amsellem now expects that the specialty pharmaceutical company will earn $2.06 per share for the year, down from their prior forecast of $2.32. Piper Jaffray has a “Buy” rating and a $33.00 price objective on the stock.

COLL has been the topic of a number of other research reports. BidaskClub lowered shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, February 23rd. Zacks Investment Research raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $26.00 price objective on the stock in a research report on Monday, April 16th. ValuEngine raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. William Blair reissued an “outperform” rating on shares of Collegium Pharmaceutical in a research report on Thursday, March 8th. Finally, Needham & Company LLC boosted their price objective on shares of Collegium Pharmaceutical from $28.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Collegium Pharmaceutical has a consensus rating of “Buy” and an average price target of $30.83.



Shares of COLL stock traded up $0.05 during trading on Friday, reaching $25.25. The company’s stock had a trading volume of 3,839 shares, compared to its average volume of 551,315. The company has a quick ratio of 0.80, a current ratio of 0.83 and a debt-to-equity ratio of 3.91. The firm has a market cap of $811.56 million, a PE ratio of -10.20 and a beta of 0.78. Collegium Pharmaceutical has a one year low of $24.26 and a one year high of $25.12.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.57) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.02). The company had revenue of $63.70 million during the quarter, compared to the consensus estimate of $51.92 million. Collegium Pharmaceutical had a negative net margin of 78.22% and a negative return on equity of 72.87%. The business’s quarterly revenue was up 2835.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.79) EPS.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Benjamin F. Edwards & Company Inc. raised its position in Collegium Pharmaceutical by 87.5% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock worth $138,000 after acquiring an additional 3,500 shares in the last quarter. Wellington Shields Capital Management LLC bought a new stake in Collegium Pharmaceutical during the first quarter worth $204,000. Stifel Financial Corp bought a new stake in Collegium Pharmaceutical during the first quarter worth $224,000. Acadian Asset Management LLC bought a new stake in Collegium Pharmaceutical during the fourth quarter worth $176,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in Collegium Pharmaceutical during the first quarter worth $260,000. 85.97% of the stock is currently owned by hedge funds and other institutional investors.

In other Collegium Pharmaceutical news, Chairman Michael Thomas Heffernan sold 44,400 shares of the company’s stock in a transaction on Thursday, April 19th. The shares were sold at an average price of $26.00, for a total transaction of $1,154,400.00. Following the sale, the chairman now directly owns 545,893 shares of the company’s stock, valued at $14,193,218. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 25.76% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply